Time to Take the Lead – Practical Utilization of SGLT2 Inhibitors

Published: 07 September 2020

  • Views:

    Views Icon 893

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

This educational symposium first broadcast at the ESC Congress 2020 discusses how SGLT2 inhibitors should be utilised by cardiologists in everyday practice

This independent medical education symposium was supported by a grant from the Boehringer Ingelheim & Eli Lilly and Company alliance.

Learning objectives

  • Understand current guidelines and utilisation of SGLT2i
  • Describe the potential mechanism of benefit of SGLT2i
  • Initiate and manage SGLT2i in appropriate patients

More from this programme

Part 1

Introduction, and No Permission Needed – Cardiology Guidelines + Prescribing Practice

1 session
Introduction, and No Permission Needed – Cardiology Guidelines + Prescribing Practice Watch now

Part 2

SGLT2i are Cardiovascular Drugs

1 session
SGLT2i are Cardiovascular Drugs Watch now

Part 3

Cardiologists Taking the Lead – How Can We Use SGLT2 Inhibitors in Our Clinical Practice?

1 session
Cardiologists Taking the Lead – How Can We Use SGLT2 Inhibitors in Our Clinical Practice? Watch now

Part 4

Case Discussion

1 session
Case Discussion Watch now

Part 5

A Follow-up Discussion to the ESC 2020 Session

1 session
A Follow-up Discussion to the ESC 2020 Session Watch now

Faculty Biographies